Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors

被引:1
作者
Li, Jun [1 ]
Li, Jie [1 ]
Zhang, Jiaojiao [1 ]
Shi, Jiantao [1 ]
Ding, Shi [1 ]
Liu, Yajing [2 ]
Chen, Ye [1 ,3 ]
Liu, Ju [1 ,3 ]
机构
[1] Liaoning Univ, Coll Pharm, Key Lab New Drug Res & Dev Liaoning Prov, Shenyang 110036, Peoples R China
[2] Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, 103 Wenhua Rd, Shenyang 110016, Peoples R China
[3] API Engn Technol Res Ctr Liaoning Prov, 66 Chongshan Rd, Shenyang 110036, Peoples R China
关键词
Synthesis; 4-phenoxypyridines; semicarbazone moieties; cytotoxic activities; c-met inhibitors; antitumor mechanism; CANCER; GROWTH; ANGIOGENESIS; METASTASIS; DISCOVERY; APOPTOSIS;
D O I
10.2174/1871520620666200101143307
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The Hepatocyte Growth Factor Receptor (HGFR) c-Met is over-expressed and/or mutated in various human tumor types. Dysregulation of c-Met/HGF signaling pathway affects cell proliferation, survival and motility, leading to tumor growth, angiogenesis, and metastasis. Therefore, c-Met has become an attractive target for cancer therapy. Objective: This study is aimed to evaluate a new series of 4-phenoxypyridine derivatives containing semicarbazones moiety for its cytotoxicity. Methods: A series of novel 4-phenoxypyridines containing semicarbazone moieties were synthesized and evaluated for their in vitro cytotoxic activities against MKN45 and A549 cancer cell lines and some selected compounds were further examined for their inhibitory activity against c-Met kinase. In order to evaluate the mechanism of cytotoxic activity of compound 24, cell cycle analysis, Annexin V/PI staining assay, AO/EB assay, wound-healing assay and docking analysis with c-Met were performed. Results: The results indicated that most of the compounds showed moderate to good antitumor activity. The compound 28 showed well cytotoxic activity against MKN45 and A549 cell lines with IC50 values of 0.25 mu M and 0.67 mu M, respectively. Compound 24 showed good activity on c-Met and its IC50 value was 0.093 mu M. Conclusion: Their preliminary Structure-Activity Relationships (SARs) studies indicated that electron-withdrawing groups on the terminal phenyl rings are beneficial for improving the antitumor activity. Treatments of MKN45 cells with compound 24 resulted in cell cycle arrest in G(2)/M phase and induced apoptosis in a dose-dependent manner. in addition, AO/EB assays indicated 24 induced dose-dependent apoptosis of A549 and MKN45 cells. Wound-healing assay results indicated that compound 24 strongly inhibited A549 cell motility.
引用
收藏
页码:559 / 570
页数:12
相关论文
共 32 条
[1]   A mini-review of c-Met as a potential therapeutic target in melanoma [J].
Al-U'datt, Doa'a G. F. ;
Al-Husein, Belal A. A. ;
Qasaimeh, Ghazi Raji .
BIOMEDICINE & PHARMACOTHERAPY, 2017, 88 :194-202
[2]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[3]  
Atreya C.E., 2013, INT J CANCER
[4]   Physiological Signaling and Structure of the HGF Receptor MET [J].
Baldanzi, Gianluca ;
Graziani, Andrea .
BIOMEDICINES, 2015, 3 (01) :1-31
[5]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[6]   Drug development of MET inhibitors: targeting oncogene addiction and expedience [J].
Comoglio, Paolo M. ;
Giordano, Silvia ;
Trusolino, Livio .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) :504-516
[7]   Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress [J].
Cui, J. Jean .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) :4427-4453
[8]   BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro [J].
Dai, Yao ;
Siemann, Dietmar W. .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (06) :1554-1561
[9]  
Garajova I., 2015, TRANSL ONCOGENOMI S1, V7, P13
[10]   Therapeutic Protein Kinase Inhibitors [J].
Grant, S. K. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2009, 66 (07) :1163-1177